Scarica l'app Stockscreener
16.86
10.18%
-1.91
Precedente Chiudi:
$18.77
Aprire:
$18.7
Volume 24 ore:
1.41M
Relative Volume:
2.36
Capitalizzazione di mercato:
$1.00B
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-8.9206
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
-22.70%
1M Prestazione:
-16.95%
6M Prestazione:
-14.24%
1 anno Prestazione:
-26.70%
Intervallo 1D:
$16.62
$18.81
Intervallo di 1 settimana:
$16.62
$22.07
Portata 52W:
$13.30
$25.37
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
16.86 | 1.11B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock - MarketBeat
Enliven Therapeutics (Nasdaq: ELVN) approves 875K-share inducement option for CEO at $18.77 - Stock Titan
Enliven Therapeutics appoints Rick Fair as new CEO - Investing.com
Enliven Therapeutics, Inc. Announces Management Changes - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO, shares down - TradingView
Enliven Therapeutics Appoints Rick Fair as CEO - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO By Investing.com - Investing.com South Africa
Enliven Therapeutics Appoints New CEO and Director - TradingView
Enliven Therapeutics announces new CEO to drive next phase of development - marketscreener.com
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PR Newswire
Top investors say Enliven Therapeutics Inc (ELVN) ticks everything they need - setenews.com
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Yahoo Finance
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Trading the Move, Not the Narrative: (ELVN) Edition - news.stocktradersdaily.com
Enliven Therapeutics: ENABLE trial shows promise in treating atypical fusion CML - Traders Union
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Enliven Therapeutics Inc stock benefit from AI adoptionJuly 2025 Setups & Long-Term Capital Growth Strategies - moha.gov.vn
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) and PreveCeutical Medical (OTCMKTS:PRVCF) Head-To-Head Analysis - Defense World
Can Enliven Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - Newser
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound - Sahm
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Ready to Jump After Recent Trade: Enliven Therapeutics Inc (ELVN) - setenews.com
Will Enliven Therapeutics Inc. stock keep outperforming rivals2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Enliven Therapeutics Inc. stock ready for breakout2025 Volume Leaders & Long-Term Growth Stock Strategies - Newser
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8%Time to Sell? - MarketBeat
Geode Capital Management LLC Grows Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Franklin Resources Inc. Has $8.63 Million Stock Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Risks Report: Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Macro Impact & Smart Swing Trading Alerts - BỘ NỘI VỤ
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Fundamental Recap & Weekly Breakout Watchlists - BỘ NỘI VỤ
Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? - MSN
(ELVN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Enliven Therapeutics Inc (ELVN) is looking forward to a strong quarter - setenews.com
SG Americas Securities LLC Buys 23,261 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics targets CML drug resistance breakthrough - Traders Union
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $279,125.00 in Stock - MarketBeat
Enliven Therapeutics Insider Sold Shares Worth $279,155, According to a Recent SEC Filing - MarketScreener
Officer Lyssikatos Sells 12,500 ($279.2K) Of Enliven Therapeutics Inc [ELVN] - TradingView
[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity - Stock Titan
Will Enliven Therapeutics Inc. stock outperform international peersWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
How Enliven Therapeutics Inc. stock reacts to Fed rate cutsGlobal Markets & Daily Technical Forecast Reports - newser.com
Why Enliven Therapeutics Inc. stock is favored by pension fundsWall Street Watch & Low Drawdown Investment Ideas - newser.com
What hedge fund activity signals for Enliven Therapeutics Inc. stock2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Is Enliven Therapeutics Inc. stock positioned well for digital economyMarket Risk Analysis & Expert-Curated Trade Recommendations - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
Enliven Therapeutics CEO Kintz sells $272k in shares By Investing.com - Investing.com Canada
CEO Kintz Sells 12,500 ($272.7K) Of Enliven Therapeutics Inc [ELVN] - TradingView
Shareholder Lyssikatos Revocable Trust 12/15/11 Files To Sell 12,500 Of Enliven Therapeutics Inc [ELVN] - TradingView
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):